wesleykoon

wesleykoon | Joined since 2016-07-21

Investing Experience -
Risk Profile -

Followers

0

Following

0

Blog Posts

0

Threads

107

Blogs

Threads

Portfolio

Follower

Following

Summary
Total comments
107
Past 30 days
0
Past 7 days
0
Today
0

User Comments
Stock

2016-07-21 14:48 | Report Abuse

genting keep dropping

Stock

2016-07-21 12:01 | Report Abuse

hng33, what do you think about maybank share? keep dropping, do you buy it also?

Stock

2016-07-21 11:30 | Report Abuse

hng33 u, sell wa at what price?

Stock

2016-07-21 11:05 | Report Abuse

so, is it a good chance to buy bjcorp now?

Stock

2016-07-21 10:55 | Report Abuse

@hng33 r still buying genting wa? will it rebound?

Stock

2016-07-21 10:26 | Report Abuse

(吉隆坡20日讯)云顶(GENTING,3182,主板贸服组)新加坡联号公司TauRx阿兹海默药物即将在本月公布研究成果,分析员看好该结果,大幅度上调评级和目标价。
马银行研究表示,云顶持有21%股权的TauRx,将在7月26日于加拿大多伦多国际阿兹海默会议上,公布第三期两份实验结果。

该行认为,TauRx选择参与该会议,释放了正面讯号。同时,该行在细读阿兹海默论坛意见后,引述舆论表示该药物的确改善了病人认知能力。

如果药物研究成功,TauRx下一步就是获得美国食品药物批准。

该行估计TauRx市值可能达到150亿美元(600亿令吉)。若云顶选择出售该公司股权,预料会为云顶带来2令吉55仙每股盈利。

该行上调该公司评级至“买进”,目标价则从8令吉90仙提升至11令吉10仙

Stock

2016-07-21 10:24 | Report Abuse

hng33 , 1MDB news will not affect genting share price? Seem like FF is withdrawing from genting shares